Dosing & Uses
Dosage Forms & Strengths
injectable solution
- 500mcg/mL
powder for injection
- 250mcg/vial
Myloid Reconstitution Following Allogeneic or Autologous Bone Marrow Transplant
250 mcg/m²/day IV; hold dose until post-BMT ANC is <500 cells/m³ & continue until ANC>1500 cells/m³ for 3 consecutive days
Administer 2-4 hr after bone marrow infusion and >24 hr after chemotherapy or radiotherapy
If severe adverse reaction occurs, can reduce dose by 50% or temporarily discontinue until reaction ceases
Post-chemo Neutrophil Recovery in AML
250 mcg/m²/day IV over 4 hr beginning on approximately day 11 or 4 days after completion of induction treatment
If day 10 bone marrow is hypoplastic with <5% blasts; continue until ANC>1500 cells/m³ or for a max of 42 days
Stem Cell Mobilization
250 mcg/m²/day IV over 24 hr or as a daily SC dose during collection; reduce dose by 50% if WBC >50,000 cells/mm³
Post-stem Cell Transplant
250 mcg/m²/day IV over 24 hours or as a daily SC dose immediately following transplant & until ANC>1500 cells/m³ for 3 consecutive days
MDS (Off-label)
15-500 mcg/m² IV infusion qDay over 1-12 hr OR 30-500 mcg/m² continuous infusion over 24 hr
Aplastic Anemia (Off-label)
15-480 mcg/m² IV infusion qDay over 1-12 hr OR 120-500 mcg/m² continuous infusion over 24 hr
Cystic Fibrosis (Orphan)
Orphan indication sponsor
- DrugRecure Aps; Cobis Building, 2200 Copenhagen N; Denmark
Acute Radiation Syndrome (Orphan)
Orphan designation for treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome)
Sponsor
- Sanofi Genzyme; 500 Kendall Street; Cambridge, Massachusetts 02142
Dosage Forms & Strengths
powder for injection
- 250mcg/vial
Myloid Reconstitution Following Allogeneic or Autologous Bone Marrow Transplant
Safety & efficacy not eatablished; no special adverse effects reported at dosages similar to adult
250 mcg/m²/day IV over 2-4 hours after bone marrow infusion & not less than 24 hours after last dose of chemo or radiation; hold Leukine until post-BMT ANC is <500 cells/m³ & continue until ANC>1500 cells/m³ for 3 consecutive days
Administer 2-4hr after bone marrow infusion and >24hr after chemotherapy or radiotherapy
If severe adverse reaction occurs, can reduce dose by 50% or temporarily discontinue until reaction ceases
Solution has benzyl alcohol; do not administer to neonates (benzyl alcohol associated with gasping syndrome in neonates)
If severe adverse reaction occurs, can reduce dose by 50% or temporarily discontinue until reaction ceases
Myloid Reconstitution Following Allogeneic or Autologous Bone Marrow Transplant
250 mcg/m²/day IV; hold dose until post-BMT ANC is <500 cells/m³ and continue until ANC>1500 cells/m³ for 3 consecutive days
Administer 2-4 hr after bone marrow infusion and >24 hr after chemotherapy or radiotherapy
If severe adverse reaction occurs, can reduce dose by 50% or temporarily discontinue until reaction ceases
Post-chemo Neutrophil Recovery in AML
250 mcg/m²/day IV over 4 hr beginning on approximately day 11 or 4 days after completion of induction treatment
If day 10 bone marrow is hypoplastic with <5% blasts; continue until ANC>1500 cells/m³ or for a max of 42 days
Stem Cell Mobilization
250 mcg/m²/day IV over 24 hr or as a daily SC dose during collection; reduce dose by 50% if WBC >50,000 cells/mm³
Post-stem Cell Transplant
250 mcg/m²/day IV over 24 hr or as a daily SC dose immediately following transplant & until ANC>1500 cells/m³ for 3 consecutive days
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
>10%
Autologous BMT
- Abdominal pain (89%)
- Diarrhea (89%)
- Asthenia (66%)
- Malaise (57%)
- Rash (44%)
- Chest pain (11%)
- Peripheral edema (11%)
Acute myelogenous leukemia
- Fever (81%)
- Skin reaction (77%)
- Metabolic disease (58%)
- Nausea (58%)
- Vomiting (46%)
- Weight loss (37%)
Diarrhea (allogenic BMT 81%)
Nausea (allogenic BMT 70%)
Vomiting (allogenic BMT 70%)
Abdominal pain (allogenic BMT 38%)
Hyperbilirubinemia (allogenic BMT 30%)
Rigor (allogenic BMT 25%)
Cardiac dysrhythmia (BMT graft failure 25%)
Pericardial effusion (BMT graft failure 25%)
Pruritis (allogenic BMT 23%)
Increase serum BUN (allogenic BMT 23%)
Pharyngitis (allogenic BMT 23%)
Bone pain (allogenic BMT 21%)
Myalgia (BMT graft failure 18%)
Hypercholesterolemia (allogenic BMT 17%)
Hypomagnesemia (allogenic BMT 15%)
Chest pain (allogenic BMT 15%)
Hematemesis (allogenic BMT 13%)
GI hemorrhage (allogenic BMT 11%)
Intraocular hemorrhage (allogenic BMT 11%)
Dysphagia (allogenic BMT 11%)
Arthralgia (allogenic BMT 11%)
1-10%
Cardiac dysrhythmia (autologous BMT 4%)
Pericardial effusion (autologous BMT 4%)
<1%
Capillary leak syndrome
Frequency Not Defined
Anorexia
Fever
Malaise
Cerebral hemorrhage
Stomatitis
Elevated BUN and cholesterol
Renal failure
Sepsis
Warnings
Contraindications
Hypersensitivity to drug or yeast proteins
>10% leukemic myeloid blasts in bone marrow or peripheral blood
Do not administer within 24 hr preceding or following chemotherapy or radiotherapy
Cautions
Caution in fluid retention, pulmonary infiltrates, CHF, lung disease, cardiac disease, hypoxia, hepatic/renal impairment; conditions may worsen
Solution should NOT be administered to neonates due to presence of benzyl alcohol in the formulation ant its association with "gasping syndrome"
Discontinue immediately if blast cells appear or disease progression occurs
Reformulated liquid devoid of sodium EDTA now available
Treatment may induce neutralizing anti-drug antibodies; incidence of anti-sargramostim neutralizing antibodies may be related to duration of exposure
A first dose effect characterized by respiratory distress, hypoxia, flushing, hypotension , syncope, and/or tachycardia, may occur with the first dose of the cycle and resolve with appropriate symptomatic treatment; symptoms do not usually occur with subsequent doses within that cycle
Edema, capillary leak syndrome, pleural and/or pericardial effusion; fluid retention shown to be reversible with dosage reduction or discontinuation with or without concomitant use of diuretics
If there is a rapid increase in blood counts (ANC≥20,000/mm³, WBC>50,000/mm³, platelets>500,000/mm³), decrease dose by 50% or discontinue therapy; excessive blood counts should fall to normal within 3-7 days after discontinuation of therapy; monitor with differential twice weekly during treatment
Sequestration of granulocytes in pulmonary circulation and dyspnea reported; monitor respiratory symptoms during and following IV infusion; decrease infusion rate by 50% if dyspnea occurs; discontinue infusion if dyspnea persists despite reduction in rate of administration; subsequent doses may be administered at standard rate with careful monitoring
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Not known if excreted in breast milk
Pregnancy Categories
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Pharmacology
Mechanism of Action
Recombinant granulocyte macrophage colony stimulating factor; acts on hematopoietic cells to stimulate proliferation & differentiation particularly into neutrophils, monocytes/macrophages & myeloid-derived dendritic cells & some end cell function activity
Pharmacokinetics
Half-life elimination: 60 min (IV); 2.7hr (SC)
Peak plasma time: 1-3hr (SC)
Clearance: 420 mL/min/m²
Duration: WBC are at baseline within 1 week of stopping the therapy
Onset of action: 7-14 days (increase in WBC)
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
